• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHC alert in real time by email
    SC 13G 1 p24-2677sc13g.htm BAUSCH HEALTH COMPANIES INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ______________________

     

    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    Bausch Health Companies Inc.

    (Name of Issuer)
     

    Common shares, no par value

    (Title of Class of Securities)
     

    071734107

    (CUSIP Number)
     

    June 26, 2024**

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    This filing also reports the beneficial ownership of the Reporting Person as of December 31, 2021 and December 31, 2022.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 07173410713GPage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Alex Meruelo

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    36,613,058*

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED VOTING POWER

    36,613,058*

    9

    SHARED VOTING POWER

    36,613,058*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.97%*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * The information set forth on this cover page reflects information as of the date hereof. As of June 26, 2024, the date of event which requires the filing of this statement on Schedule 13G, the Reporting Person may have been deemed to beneficially own 18,358,248 Shares representing approximately 5.0% of the outstanding Shares as of such time; as of December 31, 2022, the Reporting Person may have been deemed to beneficially own 9,916,324 Shares representing approximately 2.7% of the outstanding Shares as of such time; as of December 31, 2021, the Reporting Person may have been deemed to beneficially own 20,837,901 Shares representing approximately 5.8% of the outstanding Shares as of such time.

     

     

     

    CUSIP No. 07173410713GPage 3 of 7 Pages

     

    Item (a). Name of Issuer.  
      Bausch Health Companies Inc. (the “Issuer”)  
         
    Item 1(b). Address of Issuer’s Principal Executive Offices.  
     

    2150 St. Elzear Blvd. West, Laval

    Quebec, Canada H7L4A8

     
         
    Item (a). Name of Person Filing.
       
      This statement is filed by Alex Meruelo (“Mr. Meruelo”). Mr. Meruelo is the sole trustee of Alex Meruelo Living Trust dated August 6, 1996 (the “Trust”) and the sole shareholder of the Monterey Insurance Company, Inc., a Utah corporation (“Monterey”).
       
    Item 2(b). Address of Principal Business Office.
       
      The address of the principal business office of Mr. Meruelo is 2500 E. Second Street, Reno, Nevada 89595, Attention: Management Office.

     

    Item 2(c). Place of Organization.
       
      Mr. Meruelo is a citizen of the United States of America.

     

    Item 2(d). Title of Class of Securities.
       
      Common shares, no par value (“Shares”)

     

    Item 2(e). CUSIP Number.
       
      071734107
       
    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:  
         
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);  
             
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);  
             
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);  
             
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);  
             
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);  
             
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);  
             
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);  
             
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

     

     

    CUSIP No. 07173410713GPage 4 of 7 Pages

     

      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
           
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
    specify the type of institution:                                                                  

     

    Item 4. Ownership.
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for the Reporting Person hereto and is incorporated herein by reference.
       
      The percentage ownership set forth in this Schedule 13G as of the date hereof is calculated based upon an aggregate of 367,102,862 Shares outstanding as of July 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 1, 2024.
       
      As of the date hereof, because Mr. Meruelo is the sole trustee of the Trust and sole shareholder of Monterey, and because of the family relationships described below, Mr. Meruelo may be deemed the beneficial owner of 36,613,058 Shares.  This amount consists of (i) 35,637,089 Shares held for the account of the Trust, (ii) 728,900 Shares held for the account of Monterey, (iii) 175,000 Shares in the account of Liset Meruelo, the spouse of Mr. Meruelo, (iv) 5,000 Shares in the joint account of Liset Meruelo and her mother, (v) 20,974 Shares in the account of Alexander Meruelo, an adult child of Mr. Meruelo, (vi) 31,095 Shares in the account of Alexis Meruelo, an adult child of Mr. Meruelo and (vii) 15,000 Shares in the account of Lisette Meruelo, an adult child of Mr. Meruelo.
       
      The percentage ownership set forth in this Schedule 13G as of June 26, 2024 is calculated based upon an aggregate of 366,796,721 Shares outstanding as of April 26, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the Securities and Exchange Commission on May 2, 2024.
       
      As of June 26, 2024, because Mr. Meruelo is the sole trustee of the Trust and sole shareholder of Monterey, and because of the family relationships described above, Mr. Meruelo may have been deemed the beneficial owner of 18,358,248 Shares.  This amount consists of (i) 17,382,279 Shares held for the account of the Trust, (ii) 728,900 Shares held for the account of Monterey, (iii) 175,000 Shares in the account of Liset Meruelo, (iv) 5,000 Shares in the joint account of Liset Meruelo and her mother, (v) 20,974 Shares in the account of Alexander Meruelo, (vi) 31,095 Shares in the account of Alexis Meruelo and (vii) 15,000 Shares in the account of Lisette Meruelo.
       
    The percentage ownership set forth in this Schedule 13G as of December 31, 2022 is calculated based upon an aggregate of 361,868,131 Shares outstanding as of October 28, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on November 3, 2022.

     

     

     

    CUSIP No. 07173410713GPage 5 of 7 Pages

      As of December 31, 2022, because Mr. Meruelo is the sole trustee of the Trust and sole shareholder of Monterey, and because of the family relationships described above, Mr. Meruelo may have been deemed the beneficial owner of 9,916,324 Shares. This amount consists of (i) 8,921,100 Shares held for the account of the Trust, (ii) 728,900 Shares held for the account of Monterey, (iii) 175,000 Shares in the account of Liset Meruelo, (iv) 5,000 Shares in the joint account of Liset Meruelo and her mother, (v) 30,274 Shares in the account of Alexander Meruelo, including 9,300 Shares underlying call options, (vi) 34,550 Shares in the account of Alexis Meruelo and (vii) 21,500 Shares in the account of Lisette Meruelo.

     

      The percentage ownership set forth in this Schedule 13G as of December 31, 2021 is calculated based upon an aggregate of 359,330,757 Shares outstanding as of October 28, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 2, 2021.
       
      As of December 31, 2021, because Mr. Meruelo is the sole trustee of the Trust and sole shareholder of Monterey, and because of the family relationships described above, Mr. Meruelo may have been deemed the beneficial owner of 20,837,901 Shares. This amount consists of (i) 19,102,177 Shares held for the account of the Trust, including 12,404,200 Shares underlying call options, (ii) 1,456,900 Shares held for the account of Monterey, including 678,000 Shares underlying call options, (iii) 175,000 Shares in the account of Liset Meruelo, (iv) 5,000 Shares in the joint account of Liset Meruelo and her mother, (v) 42,474 Shares in the account of Alexander Meruelo, including 21,500 Shares underlying call options, (vi) 33,850 Shares in the account of Alexis Meruelo and (vii) 22,500 Shares in the account of Lisette Meruelo.

     

      Mr. Meruelo disclaims beneficial ownership of the Shares held in the accounts of Liset Meruelo and her mother, and his adult children.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      As discussed in Item 4 above, certain securities reported are held by or on behalf of persons other than the Reporting Person, which other persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. The Reporting Person disclaims beneficial ownership of such Shares except to the extent the Reporting Person actually has or shares voting power or investment power with respect to such Shares and the reporting thereof shall not be construed as an admission that the Reporting Person is a beneficial owner of such Shares.

     

     

     

     

    CUSIP No. 07173410713GPage 6 of 7 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      By signing below the Reporting Person certifies that, to the best of his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 07173410713GPage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: August 30, 2024  
     

    /s/ Alex Meruelo

      ALEX MERUELO

     

    Get the next $BHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHC

    DatePrice TargetRatingAnalyst
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    6/13/2022$12.00Overweight
    JP Morgan
    More analyst ratings

    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wechsler Amy B was granted 1,062 shares, increasing direct ownership by 0.51% to 209,008 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:36:45 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Icahn Brett was granted 5,119 shares, increasing direct ownership by 3% to 161,899 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:35:23 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Paulson John was granted 9,659 shares, increasing direct ownership by 4% to 277,708 units (SEC Form 4)

      4 - Bausch Health Companies Inc. (0000885590) (Issuer)

      4/1/25 4:34:05 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

      LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program.We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Assoc

      1/17/25 9:25:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

      LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is

      12/12/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

      LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support t

      12/5/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch Health Companies Inc.

      SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

      8/30/24 6:12:52 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

      SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

      8/19/24 5:48:41 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

      SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

      2/13/24 4:30:26 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Financials

    Live finance-specific insights

    See more
    • Bausch Health Announces Third Quarter 2024 Results

      Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro

      10/30/24 4:05:00 PM ET
      $BHC
      $NHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Hospital/Nursing Management
    • Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

      LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t

      10/9/24 4:05:00 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Announces Second Quarter 2024 Results

      Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth

      7/31/24 12:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    SEC Filings

    See more
    • Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch Health Companies Inc. (0000885590) (Filer)

      4/30/25 4:11:13 PM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bausch Health Companies Inc.

      DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)

      4/22/25 7:00:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form CERT filed by Bausch Health Companies Inc.

      CERT - Bausch Health Companies Inc. (0000885590) (Filer)

      4/17/25 9:29:12 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bausch Health downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

      8/2/24 7:25:50 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Bausch Health with a new price target

      Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

      7/10/24 8:35:33 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health upgraded by Jefferies with a new price target

      Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously

      9/20/23 7:27:08 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bausch Health Appoints New Chief Medical Officer and Head of R&D

      LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

      12/2/24 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bausch Health Welcomes Two New Members to the Executive Leadership Team

      LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

      7/19/24 7:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

      BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing

      12/5/23 8:00:00 AM ET
      $BHC
      Biotechnology: Pharmaceutical Preparations
      Health Care